← All trials
NCT00002593
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 1994
- Primary completion
- Dec 1, 1999
- Completion date
- Mar 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 1135
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Southwest Oncology GroupLead sponsor
- Mayo ClinicStudy chair
- Harvard UniversityStudy chair
- Rutgers UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- Eastern Cooperative Oncology GroupCollaborator
- North Central Cancer Treatment GroupCollaborator
- University of PennsylvaniaStudy chair
- Cancer and Leukemia Group B (CALGB)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.